Navigation Links
San Diego-Based Wellaho Receives FDA Approval For its Mobile and Web Platform for Patients with Chronic Conditions
Date:2/19/2013

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- Sanitas, Inc., a San Diego company developing mobile and web solutions for outpatients with chronic conditions, announced today that it has received approval from the US Food and Drug Administration, (FDA) as a 510(K) class II medical device for Wellaho, its proprietary mobile and web platform.

Wellaho's Personalized Outpatient Management SystemTM - currently deployed in a number of clinical studies at UC San Diego Health Services - is a physician-directed, web-based and mobile platform that allows providers to supervise and monitor patients between office visits in a secure, HIPAA compliant environment, while enabling patients to access their medical information, monitor their condition, stream relevant educational materials and connect securely to their doctors and healthcare team.

Naser Partovi , CEO of Sanitas, Inc., said of the Wellaho system, "Patients with chronic conditions need a web of care, coming from the best that providers and technology can offer. Given the tsunami of new apps and technologies that hit the market each year, both patients and providers need the highest validation for the products and services they use. Now, with the FDA's approval, Wellaho offers one more reason for providers and patients to trust that we can provide a safe, secure, and effective solution for managing their care."

About Sanitas, Inc.

Sanitas Inc. is a privately held San Diego company founded in 2010. Wellaho is the company's proprietary web and mobile platform serving patients with chronic conditions including: diabetes, congestive heart failure, kidney disease, COPD, asthma, hypertension, breast cancer, sleep disordered breathing, and obesity. Patients can view their health records (CCDs) and easily monitor their medications, weight, exercise and activity levels, blood glucose levels, blood pressure and other symptoms. Meanwhile, the patients' doctors and medical team can use Wellaho to monitor their patients' conditions between office visits.  Social networking and self-education are integral aspects of Wellaho's platform, allowing patients and their families to learn more about their disease while staying connected to their medical team in a secure, HIPPA compliant online environment.  Sanitas is actively engaged with UC San Diego Health Services in several clinical studies including diabetes, congestive heart failure and weight management.

For more information, please contact moya@wellaho.com


'/>"/>
SOURCE Sanitas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
3. Nephros Receives 510(k) Clearance for Hemodiafiltration System
4. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
5. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
6. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
7. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
8. Alexza Receives Complete Response Letter for Adasuve™ NDA
9. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
10. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
11. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  The U.S. Food and Drug Administration today granted ... adults and pediatric patients 12 years and older with ... not received prior chemotherapy. This is the first FDA-approved ... skin cancer. "While skin cancer is one ... form called Merkel cell cancer have not had an ...
(Date:3/23/2017)... British Columbia , March 23, 2017  Sophiris ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin ... that data from its successful Phase 2a study of ... for localized prostate cancer, will be presented as a ... Annual European Association of Urology in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... ... therapy devices market to grow at a CAGR of 10.16% during ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:3/23/2017)... Raton, FL (PRWEB) , ... March 23, 2017 ... ... of dietary supplements that help improve all aspects of people’s health and nutrition, ... website for nutritional products. , Natural Subsistence develops nutritional supplements that help ...
(Date:3/23/2017)... El Segundo, CA (PRWEB) , ... March 23, ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. ... primary source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... non-steroidal skincare products, was awarded as winners of American Dreams & Good Housekeeping ... was hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ...
(Date:3/23/2017)... ... 23, 2017 , ... The Boulevard is honored to host Shriners and Masons ... be located in the Main West Entrance of The Boulevard (in front of JCPenney). ... is necessary and each child with a parent or guardian will be photographed for ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
Breaking Medicine News(10 mins):